BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 21, 2024
See today's BioWorld
Home
» Fibrogen doses first patient in phase III pancreatic cancer study
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Fibrogen doses first patient in phase III pancreatic cancer study
Oct. 24, 2019
By
Lee Landenberger
No Comments
Building on the positive phase II results reported in June 2018 for
pamrevlumab
to treat pancreatic cancer, the first dose has been administered in
Fibrogen Inc.
's phase III study in patients with unresectable locally advanced pancreatic cancer.
BioWorld
Deals and M&A
